Literature DB >> 9792168

Pharmacokinetics of 125I-labelled IgG, F(ab')2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use.

M Ismail1, M A Abd-Elsalam.   

Abstract

The immunoglobulin fractions IgG, F(ab')2 and Fab of scorpion and snake antivenoms possess pharmacokinetic characteristics that are significantly different from their respective venoms. The venoms (and their toxins) are several fold faster in their distribution into the tissues than any of the immunoglobulin fraction. In rabbits, F(ab')2 possessed the fastest disposition rate constants and the longest distribution half lives. In the physiologically based pharmacokinetic experiments carried out in mice F(ab')2 possessed the highest Cp(max), smallest AUC and the shortest t1/2beta in the different tissues while Fab had values in between IgG and F(ab')2. Rescue experiments in anaesthetized rats challenged with lethal doses of venoms or toxins and infused with border-line neutralizing doses of antivenoms, showed that rats infused with F(ab')2 completely recovered, those infused with IgG partially rescued and none of the rats infused with Fab survived. It is concluded that F(ab')2 of scorpion and snake antivenoms possess pharmacokinetic characteristics that render it the most suitable for use in serotherapy of scorpion and snake envenoming.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792168     DOI: 10.1016/s0041-0101(98)00144-5

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  8 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.

Authors:  José María Gutiérrez; Guillermo León; Bruno Lomonte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Diabody mixture providing full protection against experimental scorpion envenoming with crude Androctonus australis venom.

Authors:  Anne di Tommaso; Matthieu O Juste; Marie-France Martin-Eauclaire; Isabelle Dimier-Poisson; Philippe Billiald; Nicolas Aubrey
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

3.  The pharmacokinetics of Iranian scorpion Odonthubuthus doriae venom and the available antivenom.

Authors:  Amir Jalali; Sara Moazen; Mohammad Babaee; Simin Dadashzade; Alireza Droudi
Journal:  J Venom Res       Date:  2010-10-15

4.  The pharmacokinetics of Hemiscorpius lepturus scorpion venom and Razi antivenom following intramuscular administration in rat.

Authors:  Amir Jalali; Nazanin Bavarsad-Omidian; Mohammad Babaei; Hossein Najafzadeh; Saeed Rezaei
Journal:  J Venom Res       Date:  2012-04-24

5.  Population Pharmacokinetics of an Indian F(ab')2 Snake Antivenom in Patients with Russell's Viper (Daboia russelii) Bites.

Authors:  Geoffrey K Isbister; Kalana Maduwage; Ana Saiao; Nicholas A Buckley; Shaluka F Jayamanne; Shahmy Seyed; Fahim Mohamed; Umesh Chathuranga; Alexandre Mendes; Chandana Abeysinghe; Harindra Karunathilake; Indika Gawarammana; David G Lalloo; H Janaka de Silva
Journal:  PLoS Negl Trop Dis       Date:  2015-07-02

Review 6.  Preclinical Evaluation of the Efficacy of Antivenoms for Snakebite Envenoming: State-of-the-Art and Challenges Ahead.

Authors:  José María Gutiérrez; Gabriela Solano; Davinia Pla; María Herrera; Álvaro Segura; Mariángela Vargas; Mauren Villalta; Andrés Sánchez; Libia Sanz; Bruno Lomonte; Guillermo León; Juan J Calvete
Journal:  Toxins (Basel)       Date:  2017-05-13       Impact factor: 4.546

7.  A comparative study on the equine and camelid antivenoms upon cardiovascular changes induced with Hemiscorpius lepturus venom in rats.

Authors:  Hossein Fatemikia; Mostafa Kamyab; Ali Movahed; Mehdi Sadeghi; Euikyung Kim; Mahdi Behdani; Naser Mohammadpour Dounighi; Mehrnaz Shahrivar; Ramin Seyedian
Journal:  Iran J Basic Med Sci       Date:  2019-12       Impact factor: 2.699

8.  Research into the Causes of Venom-Induced Mortality and Morbidity Identifies New Therapeutic Opportunities.

Authors:  Kesturu S Girish; Gajanan D Katkar; Robert A Harrison; Kempaiah Kemparaju
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.